LH LABCORP HOLDINGS INC.
Services-Medical Laboratories · NYSE · SEC CIK 920148 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.0%
TTM net income YoY17.4%
TTM EPS YoY19.7%
Revenue 3-yr CAGR6.6%
Net income 3-yr CAGR14.9%
Margins
Gross margin29.0%
Operating margin10.3%
Net margin6.9%
FCF margin8.8%
EBITDA margin15.1%
Returns
ROE11.4%
ROA5.4%
ROIC (approx.)8.6%
Asset turnover0.78x
Leverage & solvency
Liabilities / assets53.2%
Debt / equity0.66x
Current ratio1.41x
Interest coverage6.52x
Cash quality & payout
Operating cash flow / net income1.81x
Accruals ratio-4.4%
Payout ratio23.6%
Capex / revenue3.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20212022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $13.95B | $13.01B | $12.16B | $11.86B | $13.14B |
| Cost of revenue | $9.94B | $9.38B | $8.80B | $8.15B | $8.14B |
| Gross profit | $4.01B | $3.62B | $3.36B | $3.71B | $4.99B |
| SG&A expense | $2.22B | $2.23B | $2.02B | $1.76B | $1.69B |
| Operating income | $1.38B | $1.09B | $725.60M | $1.44B | $3.05B |
| Interest expense | $224.10M | $208.30M | $199.60M | $179.80M | $211.80M |
| Pretax income | $728.90M | $629.70M | $504.00M | $1.10B | $2.46B |
| Income tax | $229.80M | $212.40M | $188.50M | $233.90M | $690.00M |
| Net income | $876.50M | $746.00M | $418.00M | $1.28B | $2.38B |
| EBITDA | $2.07B | $1.73B | $1.30B | $1.97B | $3.63B |
| EPS (basic) | 10.54 | 8.89 | 4.80 | 14.05 | 24.60 |
| EPS (diluted) | 10.46 | 8.84 | 4.77 | 13.97 | 24.39 |
| Dividends declared per share | 2.88 | 2.88 | 2.88 | 2.16 | — |
| Weighted avg. shares (diluted) | 83.80M | 84.40M | 87.60M | 91.60M | 97.50M |
| Balance sheet | |||||
| Cash & equivalents | $532.30M | $1.52B | $536.80M | $320.60M | $1.38B |
| Receivables | $2.10B | $1.94B | $1.91B | $1.79B | $2.26B |
| Inventory | $534.70M | $493.20M | $474.60M | $470.60M | $401.40M |
| Current assets | $4.02B | $4.81B | $3.77B | $4.62B | $5.33B |
| PP&E, net | $3.08B | $3.05B | $2.91B | $2.79B | $2.82B |
| Goodwill | $6.79B | $6.37B | $6.14B | $6.12B | $5.89B |
| Intangibles | $3.60B | $3.49B | $3.34B | $3.12B | $3.74B |
| Total assets | $18.39B | $18.38B | $16.73B | $20.16B | $20.39B |
| Current liabilities | $2.82B | $3.33B | $3.23B | $3.08B | $2.78B |
| Short-term debt | $500.10M | $1.00B | $999.80M | $301.30M | $1.50M |
| Long-term debt | $5.08B | $5.33B | $4.05B | $5.04B | $5.42B |
| Total debt | $5.58B | $6.33B | $5.05B | $5.34B | $5.42B |
| Total liabilities | $9.76B | $10.31B | $8.83B | $10.04B | $10.09B |
| Shareholders' equity | $8.62B | $8.05B | $7.88B | $10.10B | $10.27B |
| Net debt | $5.05B | $4.81B | $4.52B | $5.02B | $4.04B |
| Shares outstanding | 82.20M | 83.40M | 83.90M | 88.20M | 93.10M |
| Cash flow statement | |||||
| Operating cash flow | $1.64B | $1.59B | $1.33B | $1.96B | $3.11B |
| Capital expenditure | $434.50M | $489.90M | $453.60M | $429.30M | $421.50M |
| Free cash flow | $1.21B | $1.10B | $874.10M | $1.53B | $2.69B |
| Investing cash flow | -$1.19B | -$1.37B | -$1.17B | -$1.65B | -$884.60M |
| Financing cash flow | -$1.46B | $779.90M | -$59.30M | -$1.32B | -$2.07B |
| Depreciation & amortization | $681.10M | $643.50M | $577.30M | $537.20M | $577.00M |
| Stock-based compensation | $125.80M | $116.70M | $128.70M | $116.80M | $132.90M |
| Dividends paid | $240.70M | $243.10M | $254.00M | $195.20M | — |
| Share buybacks | $450.00M | $250.10M | $1.00B | $1.10B | $1.67B |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.